Literature DB >> 17934148

Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects.

Anna Kotronen1, Leena Juurinen, Antti Hakkarainen, Jukka Westerbacka, Anja Cornér, Robert Bergholm, Hannele Yki-Järvinen.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether type 2 diabetic patients have more liver fat than age-, sex-, and BMI-matched nondiabetic subjects and whether liver enzymes (serum alanine aminotransferase [S-ALT] and serum aspartate aminotransferase) are similarly related to liver fat in type 2 diabetic patients and normal subjects. RESEARCH DESIGN AND METHODS: Seventy type 2 diabetic patients and 70 nondiabetic subjects matched for BMI, age, and sex were studied. Liver fat ((1)H-magnetic resonance spectroscopy), body composition (magnetic resonance imaging), and biochemical markers of insulin resistance were measured.
RESULTS: The type 2 diabetic patients had, on average, 80% more liver fat and 16% more intra-abdominal fat than the nondiabetic subjects. The difference in liver fat between the two groups remained statistically significant when adjusted for intra-abdominal fat (P < 0.05). At any given BMI or waist circumference, the type 2 diabetic patients had more liver fat than the nondiabetic subjects. The difference in liver fat between the groups rose as a function of BMI and waist circumference. Fasting serum insulin (r = 0.55, P < 0.0001), fasting plasma glucose (r = 0.29, P = 0.0006), A1C (r = 0.34, P < 0.0001), fasting serum triglycerides (r = 0.36, P < 0.0001), and fasting serum HDL cholesterol (r = -0.31, P = 0.0002) correlated with liver fat similarly in both groups. The slopes of the relationships between S-ALT and liver fat were significantly different (P = 0.004). Liver fat content did not differ between the groups at low S-ALT concentrations (10-20 units/l) but was 70-200% higher in type 2 diabetic patients compared with control subjects at S-ALT concentrations of 50-200 units/l.
CONCLUSIONS: Type 2 diabetic patients have 80% more liver fat than age-, weight-, and sex-matched nondiabetic subjects. S-ALT underestimates liver fat in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934148     DOI: 10.2337/dc07-1463

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  49 in total

1.  Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy.

Authors:  Boris Guiu; Romaric Loffroy; Jean-Michel Petit; Serge Aho; Douraied Ben Salem; David Masson; Patrick Hillon; Jean-Pierre Cercueil; Denis Krause
Journal:  Eur Radiol       Date:  2009-02-27       Impact factor: 5.315

Review 2.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

4.  Noninvasive assessment of abdominal adipose tissues and quantification of hepatic and pancreatic fat fractions in type 2 diabetes mellitus.

Authors:  Manoj Kumar Sarma; Andres Saucedo; Christine Hema Darwin; Ely Richard Felker; Kavya Umachandran; Daniel Kohanghadosh; Edward Xu; Steve Raman; Michael Albert Thomas
Journal:  Magn Reson Imaging       Date:  2020-07-12       Impact factor: 2.546

5.  Effect of a Low Glycemic Index Mediterranean Diet on Non-Alcoholic Fatty Liver Disease. A Randomized Controlled Clinici Trial.

Authors:  G Misciagna; M Del Pilar Díaz; D V Caramia; C Bonfiglio; I Franco; M R Noviello; M Chiloiro; D I Abbrescia; A Mirizzi; M Tanzi; M G Caruso; M Correale; R Reddavide; R Inguaggiato; A M Cisternino; A R Osella
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

6.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

7.  Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

Authors:  Boris Guiu; Elodie Crevisy-Girod; Christine Binquet; Laurence Duvillard; David Masson; Côme Lepage; Samia Hamza; Denis Krausé; Bruno Verges; Anne Minello; Jean-Pierre Cercueil; Patrick Hillon; Jean-Michel Petit
Journal:  Eur Radiol       Date:  2011-11-20       Impact factor: 5.315

8.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 9.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

Authors:  G Targher; F Marra; G Marchesini
Journal:  Diabetologia       Date:  2008-09-02       Impact factor: 10.122

10.  Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus.

Authors:  Layla Judi; Ala Toukan; Yousef Khader; Kamel Ajlouni; M Amer Khatib
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.